PUMA BIOTECHNOLOGY, INC. — Director's Dealing 2017

Oct 2, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PUMA BIOTECHNOLOGY, INC. (PBYI)
CIK: 0001401667
Period of Report: 2017-09-29

Reporting Person: BRYCE RICHARD PAUL (SR VP, CLINICAL RESEARCH & DEV)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-09-29	COMMON STOCK	M	15000	$11.30	Acquired	42239	Direct
2017-09-29	COMMON STOCK	S	15000	$120.00	Disposed	27239	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-09-29	STOCK OPTION (RIGHT TO BUY)	$11.30	M	15000	Disposed	2022-06-26	COMMON STOCK (15000)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F2: The option is fully vested and is exercisable.